Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9, 2013

Business Wire September 5, 2013

Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update

Business Wire September 4, 2013

Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117

Business Wire August 28, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on MT, QTWW, SIAL and TMO

Accesswire August 16, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on AMRI, OSIR, RNN and SQNM

Accesswire August 16, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on HOS, NEPT, RNN and SN

Accesswire August 14, 2013

Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors

Business Wire August 7, 2013

Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering

Business Wire July 24, 2013

Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform

Business Wire July 17, 2013

Rexahn Pharmaceuticals Announce IND Submission for RX-3117

Business Wire July 15, 2013

Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds

Business Wire July 9, 2013

InvestorsGuru.com 31 Filtered Mid-Day Market Movers Recap

Investors Guru June 23, 2013

Rexahn Awarded U.S. Patent for Novel Anti-Cancer Compounds

Business Wire June 17, 2013

Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference

PR Newswire May 20, 2013

Rexahn Pharmaceuticals to Present at the 25th Annual ROTH Conference

Business Wire March 11, 2013

Rexahn Pharmaceuticals Provides Key Goals for 2013

Business Wire February 19, 2013

U.S. Food and Drug Administration Approved 30% More Drugs in 2012

Marketwired February 12, 2013

Briefing: Leading Pharma Companies to Watch in Today's Market Session

PR Newswire February 5, 2013

Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive Officer

Business Wire January 22, 2013

Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012

Marketwired January 8, 2013